CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Univo Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Univo Pharmaceuticals Ltd
HAHERESH 20,
P.O. Box 1055
Phone: +972 89448585p:+972 89448585 ASHKELON, 7878320  Israel Ticker: DPRM DPRM
Business Summary
D-Pharm Ltd. is an Israel-based drug-development company. The Company is focused on developing drugs for the treatment of central nervous system (CNS) conditions. Its area of interest is in developing medicine for degenerative and age-related disorders. The Company’s product portfolio includes three clinical Phase II drug-candidates: THR-18 for thrombolysis, to restore blood flow to the brain, heart or lungs, which completed clinical Phase I and Phase II study in acute stroke patients receiving tPA; DP-VPA for the treatment of epilepsy, migraine and manic depression, which has completed a Phase II study in patients with complex partial epilepsy, and DP-b99, which contains calcium, zinc and copper ions and is used for the protection of cells under stress in acute pancreatitis. The Company’s two technology platforms Membrane Activated Chelator and Regulated Activation of Prodrug use lipid moieties conjugated onto actives such as metal ion chelators or drugs for site specific activation.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ChaimHurvitz 63 7/15/2019 7/15/2019
Chief Executive Officer, Director GolanBitton 46 9/6/2018 9/6/2018
Vice President - Finance MoranAttar-Yossef 37 10/1/2019 10/1/2019
5 additional Officers and Directors records available in full report.

Business Names
Business Name
D-PHARM LTD.
DPRM
Thrombotech Ltd.
UNVO
UNVO-M

General Information
Number of Employees: 12 (As of 12/31/2013)
Outstanding Shares: 3,293 (As of 3/31/2024)
Stock Exchange: TLV
Fax Number: +972 89448585


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024